




Fig. 1A






Fig. 1B

Fig. 1C








Fig. 1E

Fig. 1F




Fig. 1G




Fig. 1H




Fig. 1I




Fig. 2A




Fig. 2B




Fig. 2C




Fig. 3A




Fig. 3B




Fig. 4A




Fig. 4B




Fig. 5




Fig. 6C




Fig. 6B




Fig. 6A




Fig. 6E





Fig. 6D



HT29




Fig. 7C

SKOV3






Fig. 7D



● 16D5 FoIR1 TCB ● 9D11 FoIR1 TCB ▲ DP47 TCB

Fig. 7E




Fig. 7F




Fig. 7G





Fig. 7H



● 16D5 FoIR1 TCB ▲ 9D11 FoIR1 TCB ▲ DP47 TCB

Fig. 7I




Fig. 7J




Fig. 7K







Fig. 7L



● 16D5 FoIR1 TCB ▲ 9D11 FoIR1 TCB ▲ DP47 TCB


Fig. 8





● Mov19 TCB ■ 9D11 TCB ▲ 16D5 TCB ▼ DP47 TCB

Fig. 10



SKOV3





Fig. 11B



MKN45





Fig. 11D



- +— 9D11 FoIR1 TCB
- - - ◆ - - 9D11-T102N FoIR1 TCB
- ..v.. 9D11-T102A FoIR1 TCB
- 9D11-N100S FoLR1 TCB
- 9D11-N100Q FoLR1 TCB






Fig. 12A
HRPFig. 12B
HRC

—●— 16D5 FoIR1 TCB -■- 9D11 FoIR1 TCB -▲- DP47 TCB

Fig. 12C

HB





Fig. 12D

HT29



—●— 16D5 FolR1 TCB -■- 9D11 FolR1 TCB -▲- DP47 TCB

Fig. 12E





Fig. 12F



—●— 16D5 FoIR1 TCB -●- 9D11 FoIR1 TCB -▲- DP47 TCB

Fig. 12G





Fig. 12H



—●— 16D5 FolR1 TCB -■- 9D11 FolR1 TCB -▲- DP47 TCB

HRP

Fig. 12I




Fig. 12J




Fig. 12K





Fig. 12L



—●— 16D5 FcIR1 TCB - -■- 9D11 FcIR1 TCB -▲- DP47 TCB

Fig. 12M




Fig. 12N




Fig. 12O





Fig. 12P



● 16D5 FcIR1 TCB ● 9D11 FcIR1 TCB ▲ DP47 TCB

Fig. 12Q




Fig. 12R




Fig. 12S






Fig. 12T



● 16D5 FcIR1 TCB ■ 9D11 FcIR1 TCB ▲ DP47 TCB

Fig. 12U



HT29

Fig. 12V




Fig. 12W





Fig. 12X



● 16D5 FoIR1 TCB ● 9D11 FoIR1 TCB ▲ DP47 TCB

Fig. 13A




Fig. 13B




Fig. 13C




Fig. 14A




Fig. 14B




Fig. 14C





Fig. 15



Dose ug/mouse	Half-life Days
0.1	7.5
1	5.9
10	13.6

Fig. 16




Fig. 17A




Fig. 17B




Fig. 18




Fig. 19A






Fig. 19B








Fig. 21B





Fig. 21A



--■-- DP47 TCB --●-- kappa lambda FolR1 TCB

Fig. 22B




Fig. 22D




Fig. 22A





Fig. 22C



--■-- DP47 TCB --●-- kappa lambda FolR1 TCB

Fig. 23B




Fig. 23A




Fig. 24B




Fig. 24A




Fig. 24C




Figure 1 consists of four graphs showing the effect of anti-CD4 and anti-CD8 antibodies on T cell percentages. The graphs are arranged in a 2x2 grid. The top row shows % CD4⁺/CD25⁺ T cells and % CD8⁺/CD25⁺ T cells at 48h. The bottom row shows % CD4⁺/CD69⁺ T cells and % CD8⁺/CD69⁺ T cells at 48h. Each graph plots antibody concentration (pM) on a log scale (0.01 to 10000) against the percentage of T cells (0 to 100). Three data series are shown: 36F2 TCB (solid line with filled squares), 16D5 TCB (dashed line with open circles), and DP47 TCB (dotted line with asterisks). In all cases, 36F2 TCB shows a dose-dependent increase in T cell percentage, while 16D5 TCB and DP47 TCB show no significant effect.

Legend:

- 36F2 TCB (solid line with filled squares)
- 16D5 TCB (dashed line with open circles)
- DP47 TCB (dotted line with asterisks)

Fig. 25B










Figure 1 consists of four graphs showing the effect of anti-CD25 antibody concentration on the percentage of CD4⁺ and CD8⁺ T cells at 48 hours. The graphs are arranged in a 2x2 grid. The top row shows CD4⁺ and CD8⁺ T cells, and the bottom row shows CD4⁺ and CD8⁺ T cells. The x-axis for all graphs is antibody concentration (pM) on a log scale from 0.01 to 100,000. The y-axis is the percentage of T cells, ranging from 0 to 100. Three data series are shown in each graph: 36F2 TCB (filled squares), 16D5 TCB (open circles), and DP47 TCB (asterisks). In all cases, the percentage of T cells decreases as antibody concentration increases, with 16D5 TCB showing the most significant reduction.

Legend:

- 36F2 TCB (filled square)
- 16D5 TCB (open circle)
- DP47 TCB (asterisk)



■ 36F2 TCB
● 16D5 TCB
× DP47 TCB

Fig. 27

Cell line	Binding sites	Cell line	Binding sites
Hela	2'240'716	Bronchial epithelium	492
Skov3	91'510	Choroid plexus epithelium	104
OVCAR5	22'077	Renal cortical epithelium	312
HT29	10'135	Retinal pigment epithelium	822
MKN45	54	Skov3	69'890




Fig. 28A




Fig. 28B

Fig. 29A




Fig. 29B




Fig. 30A




Fig. 30B




Fig. 31B




Fig. 31C




Fig. 31A








Fig. 32A

















Fig. 33














Fig. 35B




Fig. 35D




Fig. 35C

Fig. 36A




Fig. 36B





Fig. 36C



16D5 TCB
36F2 TCB
6E10 TCB
14B1 TCB
9C7 TCB

Fig. 36D




Fig. 36E





Fig. 36F







Fig. 38A




Fig. 38B




Fig. 38C




Fig. 38D




Fig. 38E




Fig. 38F




Fig. 39A

Group	Construct	Mouse strain	Tumor	Dose (mg/kg)	Binder	Half live (days)	Cmax (ug/ml)
A	FOIR1 TCB (clone: 16D5 W96Y/D52E)	NOG	No	0.5	16D5 W96Y/D52E	10.6	16
B	FOIR1 TCB (clone: 16D5 G49S/S93A)	NOG	No	0.5	16D5 G49S/S93A	4.35	11
C	FOIR1 TCB (clone: 16D5)	NOG	No	0.5	16D5	13.6	10
D	FOIR1 TCB (clone: 36F2)	NOG	No	0.5	36F2	3.6	9





Fig. 39B

Fig. 40A

Group	Construct	PBMC injection (day 30)	Tumor (s.c.)	Start of treatment	Dose(mg/kg)	Scheduling
A	Vehicle	10x10 ⁶	HELA	Day 32	--	once per week
B	FOLR1 TCB (clone: 16D5)	10x10 ⁶	HELA	Day 32	0.5	once per week
C	FOLR1 TCB (clone: 16D5 W96Y/D52E)	10x10 ⁶	HELA	Day 32	2.5	once per week
D	FOLR1 TCB (clone: 16D5 W96Y/D52E)	10x10 ⁶	HELA	Day 32	0.5	once per week
E	FOLR1 TCB (clone: 16D5 G49S/S93A)	10x10 ⁶	HELA	Day 32	2.5	once per week
F	FOLR1 TCB (clone: 16D5 G49S/S93A)	10x10 ⁶	HELA	Day 32	0.5	once per week

Study protocol:






Fig. 40C




Fig. 40D




Fig. 40E




Fig. 40G




Fig. 40F




Fig. 41